GlobeImmune is a biopharmaceutical company specializing in the development of Tarmogen product candidates aimed at treating cancer and infectious diseases. Established in 1995 and headquartered in Louisville, Colorado, the company operates in the biotechnology sector, focusing on immunotherapy solutions. Tarmogens are designed to activate the immune system by stimulating T cells, a subset of white blood cells, to destroy infected or malignant cells. This approach contrasts with traditional vaccines that mainly stimulate antibody production. GlobeImmune's technology targets the molecular profile that distinguishes diseased cells from normal cells, aiming at specific antigens involved in oncology and infectious diseases. The company's product pipeline includes candidates for various cancers such as mutated Ras, CEA, and Brachyury, as well as infectious diseases like HBV. GlobeImmune generates revenue through strategic collaborations and licensing agreements, including a notable partnership with Celgene for cancer treatment. The company serves a global market, primarily targeting healthcare providers, research institutions, and pharmaceutical companies.

Keywords: Tarmogen, immunotherapy, cancer treatment, infectious diseases, biotechnology, T cells, oncology, HBV, Celgene, biopharmaceutical.